1.	Safety Study of Adjuvant Vaccine to Treat Melanoma Patients Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 09-0007, NCT01079741
2.	Phase II Study of ESO-1 Peptide Vaccine in HLA-A*201 or HLA-DPB1*04 Positive Patients With Refractory Metastatic Melanoma Expressing ESO-1 Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-01-C-0032, NCI-2390, 2390, NCT00020397
3.	Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, ESO-1 Peptide Vaccination Comprising ESO-1:157-165 (165V) Peptide and Montanide ISA-51, and Interleukin-2 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-04-C-0104, NCI-6233, 6233, NCT00079144
4.	Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD2003-009, NCT00199901
5.	Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD2002-013, CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND, NCT00518206
6.	Phase I Pilot Randomized Study of Melanoma Peptide Vaccine With or Without Sargramostim (GM-CSF) in Patients With High-Risk or Metastatic Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CPMC-IRB-13824, LUDWIG-LUD00-025, NCI-G02-2068, NCT00037037
7.	Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000318803, MSKCC-03034, LUDWIG-LUD2002-014, NCT00066729
8.	Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000329920, MSKCC-03047, LUDWIG-LUD2002-004, NCT00070070
9.	Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD2002-005, NCT00106158
10.	Immunotherapy of Stage III/IV Melanoma Patients Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD 2001-003, NCT00112242
11.	NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NYU 04-53, LUD2004-006, NCT00142454
12.	NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD2003-022;NYU05-120;CUMC9147, NCT00299728
13.	A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LUD2006-001, MSKCC IRB# 07-152, NCT00616941
14.	Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
15.	Decitabine, Vaccine Therapy, and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000640517, RPCI-I-127008, I 127008, NCT00887796
16.	CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-140, 1R01CA112198-01, NCT00819806
17.	Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-15383, 106566, NCI-P-8215, NCT01008527
18.	Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 16 and over Sponsor: NCI, Other Protocol IDs: MCC-15651, NCI-8316, 8316, NCT01176474
19.	Pilot Study of Adjuvant Vaccine Therapy Comprising HLA-DP4-Restricted NY-ESO-1 p157-170 Peptide and Montanide ISA-51 in Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer That Expresses NY-ESO-1 or LAGE-1 Phase: No phase specified Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: RPCI-RP-0228, LUDWIG-LUD-02-011